Aurobindo Pharma Ltd has knowledgeable the inventory exchanges that the corporate’s wholly-owned subsidiary APL Healthcare Ltd. has obtained institution inspection report (EIR) from the USFDA, classifying its manufacturing facility at Tirupati, Andhra Pradesh, as ‘voluntary motion indicated’ (VAI).
The US FDA carried out an inspection on the firm’s unit located at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023.
Aurobindo Pharma inventory traded at ₹1,076.90 on the NSE, up by 4.26 per cent as of 1:06 pm on Wednesday.
#Aurobindo #Pharma #subsidiary #receives #USFDAs #Institution #Inspection #Report #inventory #rises